Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Temasek-Holdings"

3 News Found

Apollo, Cloudnine merge maternity and fertility businesses in Rs. 1,550 crore deal
Hospitals | May 21, 2026

Apollo, Cloudnine merge maternity and fertility businesses in Rs. 1,550 crore deal

Combined platform with 55+ centres aims to expand integrated maternity, fertility, neonatal and paediatric care across India

Alembic Pharmaceuticals appoints Manish Kejriwal as Independent Director
People | April 02, 2024

Alembic Pharmaceuticals appoints Manish Kejriwal as Independent Director

Temasek to buy a stake in Integrace
Startup | October 05, 2021

Temasek to buy a stake in Integrace

The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition

Upcoming E-conference
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Shilpa Biologicals' PartnerPower promises real-time transparency in biologics development

KIMS Hospitals launches RENOVA Oncology Institute in Bengaluru

Teva submits FDA application for experimental Tourette syndrome treatment ecopipam

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited

Packaging